<![CDATA[Replicor Inc. 보도자료 - 뉴스와이어]]>https://www.newswire.co.kr/?md=A10&act=article&no=24669>Wed, 29 Apr 2026 22:28:25 +0900Copyright (c) 2004~2026 Korea Newswire All rights reservedko-KR<![CDATA[Replicor Announces Publication of its REP 301 Study in HBV / HDV Co-Infection in The Lancet Gastroenterology & Hepatology]]>https://www.newswire.co.kr/newsRead.php?no=857136Thu, 28 Sep 2017 22:05:00 +0900<![CDATA[레플리코, HBV/HDV동시 감염 환자 대상 REP301임상시험 결과가 ‘란셋 위장병간장병학’에 게재됐다고 발표]]>https://www.newswire.co.kr/newsRead.php?no=857137Thu, 28 Sep 2017 22:05:00 +0900<![CDATA[Replicor discloses achievement of 1 year functional control of HBV and HDV with NAPs and new mechanistic insights in NAP pharmacology]]>https://www.newswire.co.kr/newsRead.php?no=848741Thu, 20 Apr 2017 23:05:00 +0900<![CDATA[레플리코, B형 및 D형 간염바이러스에 대한 NAP의 1년 기능 억제 성과 및 NAP의약품의 새로운 작용기전 발표]]>https://www.newswire.co.kr/newsRead.php?no=848742Thu, 20 Apr 2017 23:05:00 +0900<![CDATA[Replicor Discloses Updated REP 401 Clinical Data at APASL 2017]]>https://www.newswire.co.kr/newsRead.php?no=844970Mon, 13 Feb 2017 10:25:00 +0900<![CDATA[레플리코, APASL 2017에서 업데이트된 REP401 임상 자료 발표]]>https://www.newswire.co.kr/newsRead.php?no=844971Mon, 13 Feb 2017 10:25:00 +0900<![CDATA[Replicor to Disclose Late Breaking HBV Clinical Data at AASLD 2016]]>https://www.newswire.co.kr/newsRead.php?no=836573Tue, 04 Oct 2016 21:00:00 +0900<![CDATA[레플리코, AASLD 2016에서 획기적인 최신 HBV 임상 데이터 공개]]>https://www.newswire.co.kr/newsRead.php?no=836574Tue, 04 Oct 2016 21:00:00 +0900<![CDATA[Replicor to Present Pre-Clinical and Updated Clinical Data on REP 2139-Ca Based Combination Therapy in Chronic HBV and HBV / HDV Co-Infection at APASL 2016]]>https://www.newswire.co.kr/newsRead.php?no=817706Tue, 16 Feb 2016 22:00:00 +0900<![CDATA[레플리코, APASL 2016에서 만성 B형 간염바이러스 및 B형/D형 간염 바이러스 동시감염에 대한 ‘REP 2139-Ca’ 기반 복합요법의 전임상 및 업데이트된 임상자료 발표]]>https://www.newswire.co.kr/newsRead.php?no=817707Tue, 16 Feb 2016 22:00:00 +0900<![CDATA[Replicor Discloses Continued Improvement of the Antiviral Response in Patients with HBV / HDV Co-Infection Receiving REP 2139-Ca Based Combination Therapy]]>https://www.newswire.co.kr/newsRead.php?no=809779Mon, 16 Nov 2015 22:00:00 +0900<![CDATA[레플리코, “REP 2139-Ca 기반 복합요법 받은 HBV/HDV 동시감염 환자에서 항바이러스 반응 지속 개선”]]>https://www.newswire.co.kr/newsRead.php?no=809781Mon, 16 Nov 2015 22:00:00 +0900<![CDATA[Replicor Announces Publication of Its Pre-Clinical Data on the Therapeutic Effect of NAPs on Hepatitis B Virus Infection.]]>https://www.newswire.co.kr/newsRead.php?no=809464Thu, 12 Nov 2015 14:25:00 +0900<![CDATA[레플리코, B형 간염 바이러스 감염에서 NAP의 치료효과에 대한 전임상 데이터 공개]]>https://www.newswire.co.kr/newsRead.php?no=809466Thu, 12 Nov 2015 14:25:00 +0900<![CDATA[Replicor Announces Grant of US Patents on HBV / HDV Treatment Methods Combining HBsAg Reduction and Immunotherapy]]>https://www.newswire.co.kr/newsRead.php?no=809031Mon, 09 Nov 2015 22:00:00 +0900<![CDATA[레플리코, HBsAg항원 감소 및 면역치료를 결합한 HBV / HDV 치료법 미국 특허 승인 발표]]>https://www.newswire.co.kr/newsRead.php?no=809033Mon, 09 Nov 2015 22:00:00 +0900<![CDATA[Replicor Announces Initiation of Recruitment for Its Phase IIb Clinical Trial with REP 2139-Mg or REP 2165-Mg in Combination with Viread® and Pegasys® or Zadaxin® in Patients with HBeAg Negative Chronic Hepatitis B Infection]]>https://www.newswire.co.kr/newsRead.php?no=805490Tue, 06 Oct 2015 13:35:00 +0900<![CDATA[레플리코, HBeAg 음성 만성 B형 간염 환자 대상 REP 2139-Mg 또는 REP 2165-Mg와 Viread®, Pegasys® 또는 Zadaxin® 병용 제2상 후기 임상시험 참가자 모집 개시]]>https://www.newswire.co.kr/newsRead.php?no=805496Tue, 06 Oct 2015 13:35:00 +0900<![CDATA[Replicor to Present at the 2015 Lancet Viral Hepatitis Conference]]>https://www.newswire.co.kr/newsRead.php?no=788527Fri, 10 Apr 2015 19:00:00 +0900<![CDATA[레플리코, 2015 란셋 바이러스성 간염 컨퍼런스 참가]]>https://www.newswire.co.kr/newsRead.php?no=788528Fri, 10 Apr 2015 19:00:00 +0900